GNI Group Ltd
3G6
Company Profile
Business description
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
Contact
Shinjuku Park Tower
3-7-1 Nishi-Shinjuku
Shinjuku-ku
Tokyo163-1030
JPNT: +81 353263097
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
896
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,101.50 | 21.00 | -0.23% |
| CAC 40 | 7,818.22 | 78.71 | -1.00% |
| DAX 40 | 23,329.24 | 419.62 | -1.77% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,195.66 | 81.37 | -0.88% |
| HKSE | 26,636.93 | 198.42 | 0.75% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,992.14 | 89.87 | 0.20% |
| NZX 50 Index | 13,163.37 | 71.52 | -0.54% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,826.10 | 22.40 | -0.25% |
| SSE Composite Index | 3,854.36 | 7.51 | -0.19% |